Tag: indian biotech and pharma shift us operations regulatory policy ciicon pharmicon

Held in Hyderabad, the ICON-CII event brought together pharma leaders, policy makers, and investors to explore the strategic imperatives of expanding Indian manufacturing to the United States.

The Confederation of Indian Industry (CII) Telangana and U.S.-based construction and project delivery firm ICON jointly hosted the first Indian edition of “PharmiCON” in Hyderabad. With a theme focused on “Navigating the Road Ahead for U.S.-Based Manufacturing,” the event spotlighted Indian pharma’s evolving global strategy and the growing relevance of building capabilities across international markets, particularly in the United States.
The event opened with remarks from CII Telangana Past Chairman Mr. Sanjay Singh and CII Pharma and Life Sciences Panel Convener Mr. Chakravarthi AVPS. Their address emphasized the importance of resilience and global competitiveness as Indian companies confront shifting regulations and rising expectations from global regulators and partners.

ICON’s CEO and Founder Mr. Bhupendra Patel highlighted the company’s deep-rooted experience in constructing pharmaceutical and biopharma facilities in the U.S., noting over $300 million in project value, more than 200 sites, and over 1 million square feet of built space. He shared how ICON offers end-to-end support from land acquisition to design, execution, and operational handover for Indian pharma and biotech firms looking to enter or expand in the U.S. market.
Telangana government’s participation was marked by the presence of Mr. Venugopal Rao Sankineni, Vice President for Medical Devices (Policy & Investments) at Telangana Lifesciences. He positioned the state as a leading catalyst for global-scale pharma and medtech innovation.

A whitepaper titled “Changing Landscape: Indian Pharma’s Move Towards U.S.-Based Manufacturing” was also launched at the event, co-authored by ICON and CII with Healthark as the knowledge partner. The report explores how new U.S. policies including the Inflation Reduction Act and the BIOSECURE Act are creating both constraints and opportunities for Indian companies, particularly in areas such as biologics, injectables, and contract manufacturing.

Two panel discussions addressed the critical factors shaping this evolution: the first focused on the logistics, incentives, and risks of U.S.-based operations, while the second explored global supply chain recalibration in the context of recent geopolitical changes.
Concluding the event, Mr. Chakravarthi AVPS reiterated that the Indian pharmaceutical sector is at a pivotal point where timely international investment, especially in U.S. manufacturing, could enhance long-term trust, capacity, and global standing in the life sciences domain.

At Prittle Prattle News, we honor your dedication and inventiveness led by showcasing you in a positive light. Under the direction of Editor-in-Chief Smruti Bhalerao, our platform is committed to disseminating powerful narratives that raise awareness and motivate change. For more important stories, follow us on LinkedIn, Instagram, and YouTube.